NCT05600387View on ClinicalTrials.gov

Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 5, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2025

Conditions
Heart FailureHeart Failure With Preserved Ejection FractionHeart Failure With Mid Range Ejection Fraction
Interventions
DRUG

Empagliflozin 10 MG

subjects in Empagliflozin group take 10mg Empagliflozin per day

Trial Locations (1)

110004

Shengjing Hospital, Shenyang

All Listed Sponsors
lead

Zhijun Sun

OTHER